0000950170-24-016797.txt : 20240220 0000950170-24-016797.hdr.sgml : 20240220 20240220070536 ACCESSION NUMBER: 0000950170-24-016797 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240220 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240220 DATE AS OF CHANGE: 20240220 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Axsome Therapeutics, Inc. CENTRAL INDEX KEY: 0001579428 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 454241907 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37635 FILM NUMBER: 24650677 BUSINESS ADDRESS: STREET 1: ONE WORLD TRADE CENTER, 22ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10007 BUSINESS PHONE: (212) 332-3241 MAIL ADDRESS: STREET 1: ONE WORLD TRADE CENTER, 22ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10007 8-K 1 axsm-20240220.htm 8-K 8-K
0001579428false00015794282024-02-202024-02-20

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 20, 2024

 

 

Axsome Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37635

45-4241907

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

One World Trade Center, 22nd Floor

 

New York, New York

 

10007

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (212) 332-3241

 

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, Par Value $0.0001 Per Share

 

AXSM

 

Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 2.02 Results of Operations and Financial Condition.

On February 20, 2024, Axsome Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months and fiscal year ended December 31, 2023 and provided an update on the Company’s operations. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

Description

99.1

Press Release dated February 20, 2024.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Axsome Therapeutics, Inc.

 

 

 

 

Date:

February 20, 2024

By:

/s/ Herriot Tabuteau, M.D.

 

 

Name:

Title:

Herriot Tabuteau, M.D.
President and Chief Executive Officer

 

 EX-99.1 2 axsm-ex99_1.htm EX-99.1 EX-99.1

Exhibit 99.1

img36028404_0.jpg 

 

 

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

 

Total 4Q and full year 2023 net product revenue of $71.5 million and $204.9 million, respectively, representing year-over-year growth of 193% and 309%

 

Auvelity 4Q and full year 2023 net product sales of $49.0 million and $130.1 million, respectively, during the first full year of launch

 

Sunosi 4Q and full year 2023 net product revenue of $22.5 million and $74.8 million, respectively, representing 17% and 67% year-over-year growth

 

NDA submission for AXS-14 in fibromyalgia and NDA resubmission for AXS-07 in migraine, both anticipated in 1H 2024

 

Topline results of the SYMPHONY Phase 3 trial in narcolepsy anticipated in 1Q 2024

 

Topline results of the ADVANCE-2 Phase 3 trial in Alzheimer’s disease agitation and the FOCUS Phase 3 trial in ADHD expected in 2H 2024

 

Initiation of Phase 3 trials of solriamfetol in major depressive disorder, binge eating disorder, and shift work disorder expected 1Q 2024

 

NEW YORK, Feb. 20, 2024 (Globe Newswire) – Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced reported financial results for the fourth quarter and full year of 2023.

“2023 was a transformational year for Axsome, based on successful commercial execution as well as substantial pipeline advancement and expansion. During our first full year as a commercial company, Auvelity and Sunosi were prescribed for more than 100,000 patients combined. We expanded our Auvelity neuropsychiatry sales force and progressed our NDAs for AXS-07 in migraine and AXS-14 in fibromyalgia. We advanced our Phase 3 trials of AXS-12 in narcolepsy and AXS-05 in Alzheimer’s disease agitation, initiated a Phase 3 pivotal trial program for solriamfetol in ADHD, and announced three additional new indications for solriamfetol,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “We expect to continue the momentum in 2024 as we drive further growth for our two currently marketed products, and potentially submit two NDAs for migraine and fibromyalgia, read out three Phase 3 trials in narcolepsy, Alzheimer’s disease agitation, and ADHD, and, in the near term, initiate an equal number of new pivotal trials in depression, binge eating disorder, and shift work disorder. Enrollment in the SYMPHONY Phase 3 trial of AXS-12 in narcolepsy is now complete and we are on track to report topline results this quarter.”

Fourth Quarter 2023 and Full Year Financial Highlights

•
Total net product revenues were $71.5 million and $204.9 million for the fourth quarter and full year of 2023, representing year-over-year growth of 193% and 309%, respectively. Total product revenues for the comparable periods in 2022 were $24.4 million and $50.0 million, respectively. Total revenue for the full year of 2023 was $270.6 million, which includes license revenue of $65.7 million from out-licensing Sunosi® in certain ex-U.S. territories.
•
Auvelity® net product sales were $49.0 million and $130.1 million for the fourth quarter and full year of 2023, the first full year of launch. Auvelity was launched on October 19, 2022, and had U.S. net sales of $5.2 million for the fourth quarter of 2022.

1

 

 

•
Sunosi net product revenues were $22.5 million and $74.8 million for the fourth quarter and full year of 2023, representing 17% and 67% year-over-year growth, respectively, consisting of $21.7 million and $72.4 million in net product sales and $0.8 million and $2.4 million in royalty revenue associated with Sunosi sales in out-licensed territories, respectively. Sunosi net sales for the comparable periods in 2022 were $19.2 million and $44.9 million, respectively. The U.S. portion of the acquisition of Sunosi closed in May 2022 and the ex-U.S. portion closed in November of 2022. Total Sunosi revenue for the full year of 2023 was $140.5 million, which includes license revenue of $65.7 million from out-licensing Sunosi in certain ex-U.S. territories.
•
Total costs of revenue were $7.4 million and $26.1 million for the fourth quarter and full year of 2023, respectively. Total costs of revenue for the comparable periods in 2022 was $2.3 million and $5.2 million, respectively. Total cost of revenue for the full year of 2023 included a one-time cost of $5.0 million associated with the upfront fee received for the Sunosi out licensing transaction.
•
Research and development (R&D) expenses were $30.8 million and $97.9 million for the fourth quarter and full year of 2023, respectively, compared to $14.7 million and $57.9 million for the comparable periods in 2022, respectively. The increase was primarily related to the FOCUS trial of solriamfetol in ADHD, the advancement of ongoing trials of AXS-05 and AXS-12, manufacturing costs associated with the anticipated NDAs for AXS-07 and AXS-14, post-marketing commitments for Auvelity and Sunosi, and higher personnel costs, including non-cash stock-based compensation.
•
Selling, general, and administrative (SG&A) expenses were $86.8 million and $323.1 million for the fourth quarter and full year of 2023, respectively, compared to $61.5 million and $159.3 million for the comparable periods in 2022, respectively. The increase was primarily related to commercialization activities for Auvelity and Sunosi, including sales force and marketing expenses, and higher personnel costs related to organizational growth, including non-cash stock-based compensation.
•
Net loss for the fourth quarter of 2023 was $98.7 million or $(2.08) per share, compared to a net loss of $61.2 million, or $(1.41) per share, for the comparable period in 2022. The net loss in the fourth quarter of 2023 includes $63.7 million in non-cash charges, comprised of $43.2 million in acquisition-related contingent consideration expense reflecting updated sales projections for the recently announced new indications in solriamfetol, $18.9 million of non-cash stock-based compensation expense, and $1.6 million of non-cash intangible asset amortization. Net loss was $239.2 million, or $(5.27) per share, for the full year of 2023, compared to a net loss of $187.1 million, or $(4.60) per share, for the full year of 2022. The net loss for the full year includes total non-cash charges of $117.9 million which includes $62.6 million of stock-based compensation expense, $48.9 million in fair value of contingent consideration expense, and $6.4 million in intangible amortization compared to $37.7 million, $3.3 million, and $4.1 million respectively for the full year 2022.
•
Cash and cash equivalents totaled $386.2 million at December 31, 2023, compared to $200.8 million at December 31, 2022.
•
Shares of common stock outstanding were 47,351,363 at December 31, 2023.

Financial Guidance

•
Axsome believes that its current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan.

2

 

 

Commercial Highlights

Auvelity

•
Approximately 84,000 prescriptions were written for Auvelity in the fourth quarter of 2023, representing a 23% sequential increase versus the third quarter of 2023.
•
The previously announced expansion of the Auvelity neuropsychiatry sales force from 162 to 260 representatives is now complete. The sales force expansion along with Axsome’s pioneering, technology-driven Digital Centric Commercialization (DCC™) platform is expected to increase our reach to approximately 44,000 health care providers, who write nearly 90% of new branded antidepressant prescriptions.
•
Payer coverage for Auvelity across all channels is stable at approximately 70% of all covered lives. Commercial coverage is at approximately 48%, and Auvelity is a protected class product which must be covered by all payors in the Medicare channel and is covered by all state Medicaid programs. Axsome expects coverage to continue to expand and evolve.

Sunosi

•
Approximately 42,000 prescriptions were written for Sunosi in the U.S. in the fourth quarter of 2023, representing an 18% increase versus the fourth quarter of 2022 and a 2% sequential increase versus the third quarter of 2023.

 

•
Sunosi maintains broad payer coverage in the commercial channel with 95% of lives covered. Currently 83% of total lives across all channels are covered.

Development Pipeline

Axsome is advancing an industry-leading neuroscience portfolio encompassing five innovative, late-stage, patent-protected product candidates for 10 serious psychiatric and neurologic conditions, which affect more than 150 million people in the U.S. alone. Recent and anticipated progress for key pipeline programs is summarized below.

AXS-05

AXS-05 (dextromethorphan-bupropion) is Axsome’s novel, oral, investigational NMDA receptor antagonist and sigma-1 agonist being developed for Alzheimer’s disease (AD) agitation and smoking cessation. AXS-05 has been granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for AD agitation.

•
Alzheimer’s Disease Agitation: The Company is conducting the ADVANCE-2 study, a Phase 3, placebo-controlled, parallel group trial to assess the efficacy and safety of AXS-05 for the treatment of AD agitation. Patients completing ADVANCE-2 may enter a long-term open label safety extension trial. Based on anticipated enrollment trends and recent changes to treatment market dynamics, the Company now anticipates completion of ADVANCE-2 in the second half of 2024.
•
Smoking Cessation: Axsome plans to initiate a pivotal Phase 2/3 trial in this indication in 2024.

3

 

 

AXS-07

AXS-07 (MoSEIC™ meloxicam-rizatriptan) is Axsome’s novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine for the acute treatment of migraine.

•
Migraine: Manufacturing activities related to the planned resubmission of the New Drug Application (NDA) for AXS-07 for the acute treatment of migraine continue to progress. The Company continues to anticipate resubmission of the NDA in the first half of 2024. No additional clinical efficacy or safety trials have been requested by the FDA for a resubmission of the NDA. The Company expects the NDA resubmission to be designated as Class 2 which would be subject to a six-month review.

AXS-12

AXS-12 (reboxetine) is Axsome’s novel, oral, potent, investigational highly selective norepinephrine reuptake inhibitor for the treatment of narcolepsy. AXS-12 has been granted FDA Orphan Drug designation for the treatment of narcolepsy.

•
Narcolepsy: Enrollment in the SYMPHONY study, a Phase 3 randomized, multicenter, double-blind, placebo-controlled, parallel-group trial of AXS-12 in the treatment of narcolepsy has been completed. The Company is on track to announce topline results for SYMPHONY in the first quarter of 2024.

AXS-14

AXS-14 (esreboxetine) is Axsome’s novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor for the management of fibromyalgia. Esreboxetine, the SS-enantiomer of reboxetine, is more potent and selective than racemic reboxetine.

•
Fibromyalgia: Axsome is compiling the NDA for AXS-14 for the management of fibromyalgia. The Company is on track to submit the NDA in the first half of 2024. AXS-14 has previously met the primary endpoints and demonstrated positive and statistically significant results in a Phase 3 and in a Phase 2 trial for the management of fibromyalgia.

Solriamfetol

Solriamfetol is Axsome’s dopamine and norepinephrine reuptake inhibitor and TAAR1 agonist in development for the treatment of attention deficit hyperactivity disorder (ADHD), major depressive disorder (MDD), binge eating disorder (BED), and excessive sleepiness associated with shift work disorder (SWD).

•
Attention Deficit Hyperactivity Disorder: Axsome is conducting the FOCUS study, a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of ADHD in adults. The Company anticipates topline results from the FOCUS trial in the second half of 2024.
•
Major Depressive Disorder: The Company plans to initiate a Phase 3 trial of solriamfetol for the treatment of MDD in the first quarter of 2024.
•
Binge Eating Disorder: The Company plans to initiate a Phase 3 trial of solriamfetol for the treatment of BED in the first quarter of 2024.
•
Shift Work Disorder: The Company plans to initiate a Phase 3 trial of solriamfetol for the treatment of excessive sleepiness (ES) associated with SWD in the first quarter of 2024.

4

 

 

Anticipated Milestones

•
Regulatory and Commercial:
o
AXS-07 for migraine, NDA resubmission (1H 2024)
o
AXS-14 for fibromyalgia, NDA submission (1H 2024)
•
Clinical Trial Topline Results:
o
Phase 3 SYMPHONY trial of AXS-12 in narcolepsy (1Q 2024)
o
Phase 3 ADVANCE-2 trial of AXS-05 for Alzheimer’s disease agitation (2H 2024)
o
Phase 3 FOCUS trial of solriamfetol in attention deficit hyperactivity disorder (ADHD) in adults (2H 2024)
•
Clinical Trial Initiations:
o
Phase 3 trial of solriamfetol in major depressive disorder (MDD) (1Q 2024)
o
Phase 3 trial of solriamfetol for binge eating disorder (BED) (1Q 2024)
o
Phase 3 trial of solriamfetol in shift work disorder (SWD) (1Q 2024)
o
Pivotal Phase 2/3 trial of AXS-05 for smoking cessation (2024)

 

Conference Call Information

Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss fourth quarter and full year 2023 financial results as well as to provide a corporate update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic). The live webcast can be accessed on the "Webcasts & Presentations" page of the "Investors" section of the Company’s website at axsome.com. A replay of the webcast will be available for approximately 30 days following the live event.

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are committed to developing products that meaningfully improve the lives of patients and provide new therapeutic options for physicians. For more information, please visit the Company’s website at axsome.com. The Company may occasionally disseminate material, nonpublic information on the company website.

Forward Looking Statements

Certain matters discussed in this press release are “forward-looking statements”. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the continued commercial success of our Sunosi® and Auvelity® products and the success of our efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed

5

 

 

clinical trials, which assumes no material changes to our currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of our ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of our current product candidates; our ability to fund additional clinical trials to continue the advancement of our product candidates; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, our product candidates, including statements regarding the timing of any NDA submission; whether issues identified by FDA in the complete response letter may impact the potential approvability of the Company’s NDA for AXS-07 for the acute treatment of migraine in adults with or without aura, pursuant to our special protocol assessment for the MOMENTUM clinical trial; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the continued commercialization of Sunosi and Auvelity and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; unforeseen circumstances or other disruptions to normal business operations arising from or related to geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.

 

 

6

 

 

Axsome Therapeutics, Inc.

Selected Consolidated Financial Data

 

Axsome Therapeutics, Inc.

Consolidated Balance Sheets

(Unaudited, in thousands, except for share and per share amounts)

 

 

 

December 31,

 

 

December 31,

 

 

 

2023

 

 

2022

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

386,193

 

 

$

200,842

 

Accounts receivables, net

 

 

94,820

 

 

 

37,699

 

Inventories, net

 

 

15,135

 

 

 

4,320

 

Prepaid and other current assets

 

 

8,115

 

 

 

2,781

 

Total current assets

 

 

504,263

 

 

 

245,642

 

Equipment, net

 

 

846

 

 

 

722

 

Right-of-use asset - operating lease

 

 

6,772

 

 

 

420

 

Goodwill

 

 

12,042

 

 

 

10,310

 

Intangible asset, net

 

 

53,286

 

 

 

59,661

 

Non-current inventory and other assets

 

 

11,027

 

 

 

14,721

 

Total assets

 

$

588,236

 

 

$

331,476

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

40,679

 

 

$

38,605

 

Accrued expenses and other current liabilities

 

 

90,501

 

 

 

51,631

 

Operating lease liability, current portion

 

 

1,267

 

 

 

425

 

Contingent consideration, current

 

 

6,407

 

 

 

5,900

 

Total current liabilities

 

 

138,854

 

 

 

96,561

 

Contingent consideration, non-current

 

 

73,300

 

 

 

31,100

 

Loan payable, long-term

 

 

178,070

 

 

 

94,259

 

Operating lease liability, long-term

 

 

7,035

 

 

 

—

 

Total liabilities

 

 

397,259

 

 

 

221,920

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.0001 par value per share (10,000,000 shares authorized, none issued and outstanding)

 

 

—

 

 

 

—

 

Common stock, $0.0001 par value per share (150,000,000 shares authorized, 47,351,363 and 43,498,617 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively)

 

 

5

 

 

 

4

 

Additional paid-in capital

 

 

1,026,543

 

 

 

705,885

 

Accumulated deficit

 

 

(835,571

)

 

 

(596,333

)

Total stockholders’ equity

 

 

190,977

 

 

 

109,556

 

Total liabilities and stockholders’ equity

 

$

588,236

 

 

$

331,476

 

 

 

 

7

 

 

Axsome Therapeutics, Inc.

Consolidated Statements of Operations

(Unaudited, in thousands, except share and per share amounts)

 

 

 

Three Months Ended

 

 

Twelve Months Ended

 

 

 

December 31,

 

 

December 31,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Product sales, net

 

$

70,747

 

 

$

24,372

 

 

$

202,460

 

 

$

50,037

 

License revenue

 

 

—

 

 

 

—

 

 

 

65,735

 

 

 

—

 

Royalty revenue

 

 

784

 

 

 

—

 

 

 

2,405

 

 

 

—

 

Total revenues

 

 

71,531

 

 

 

24,372

 

 

 

270,600

 

 

 

50,037

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue (excluding amortization and depreciation)

 

 

7,377

 

 

 

2,291

 

 

 

26,065

 

 

 

5,198

 

Research and development

 

 

30,803

 

 

 

14,693

 

 

 

97,944

 

 

 

57,947

 

Selling, general and administrative

 

 

86,810

 

 

 

61,498

 

 

 

323,123

 

 

 

159,254

 

Loss in fair value of contingent consideration

 

 

43,207

 

 

 

4,200

 

 

 

48,918

 

 

 

3,298

 

Intangible asset amortization

 

 

1,607

 

 

 

1,607

 

 

 

6,375

 

 

 

4,139

 

Total operating expenses

 

 

169,804

 

 

 

84,289

 

 

 

502,425

 

 

 

229,836

 

Loss from operations

 

 

(98,273

)

 

 

(59,917

)

 

 

(231,825

)

 

 

(179,799

)

Interest expense, net

 

 

(703

)

 

 

(1,323

)

 

 

(6,453

)

 

 

(7,335

)

Loss before income taxes

 

 

(98,976

)

 

 

(61,240

)

 

 

(238,278

)

 

 

(187,134

)

Income tax benefit (expense)

 

 

325

 

 

 

—

 

 

 

(960

)

 

 

—

 

Net loss

 

$

(98,651

)

 

$

(61,240

)

 

$

(239,238

)

 

$

(187,134

)

Net loss per common share, basic and diluted

 

$

(2.08

)

 

$

(1.41

)

 

$

(5.27

)

 

$

(4.60

)

Weighted average common shares outstanding, basic and diluted

 

 

47,329,782

 

 

 

43,447,309

 

 

 

45,425,212

 

 

 

40,655,941

 

 

Axsome Contacts:

Investors:

Mark Jacobson

Chief Operating Officer

Axsome Therapeutics, Inc.

One World Trade Center, 22nd Floor

New York, NY 10007

Tel: 212-332-3243

Email: mjacobson@axsome.com

www.axsome.com

 

Media:

Darren Opland

Director, Corporate Communications

Axsome Therapeutics, Inc.

One World Trade Center, 22nd Floor

New York, NY 10007

Tel: 929-837-1065

Email: dopland@axsome.com

www.axsome.com

8

 GRAPHIC 3 img36028404_0.jpg GRAPHIC begin 644 img36028404_0.jpg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end EX-101.SCH 4 axsm-20240220.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document And Entity Information
Feb. 20, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 20, 2024
Entity Registrant Name Axsome Therapeutics, Inc.
Entity Central Index Key 0001579428
Entity Emerging Growth Company false
Entity File Number 001-37635
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 45-4241907
Entity Address, Address Line One One World Trade Center, 22nd Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10007
City Area Code (212)
Local Phone Number 332-3241
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, Par Value $0.0001 Per Share
Trading Symbol AXSM
Security Exchange Name NASDAQ
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports axsm-20240220.htm axsm-20240220.xsd http://xbrl.sec.gov/dei/2023 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "axsm-20240220.htm": { "nsprefix": "axsm", "nsuri": "http://axsome.com/20240220", "dts": { "inline": { "local": [ "axsm-20240220.htm" ] }, "schema": { "local": [ "axsm-20240220.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_3352a066-0271-4415-9438-79e483832ef2", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "axsm-20240220.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3352a066-0271-4415-9438-79e483832ef2", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "axsm-20240220.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://axsome.com/20240220/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0000950170-24-016797-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-016797-xbrl.zip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end XML 15 axsm-20240220_htm.xml IDEA: XBRL DOCUMENT 0001579428 2024-02-20 2024-02-20 0001579428 false 8-K 2024-02-20 Axsome Therapeutics, Inc. DE 001-37635 45-4241907 One World Trade Center, 22nd Floor New York NY 10007 (212) 332-3241 false false false false Common Stock, Par Value $0.0001 Per Share AXSM NASDAQ false